

# ***Dr. Katja Giersch***

---

Geburtsdatum: 25. Oktober 1984  
Geburtsort: Berlin

Anschrift: I. Medizinische Klinik und Poliklinik  
Universitätsklinikum Hamburg-Eppendorf  
Martinistraße 52  
20246 Hamburg

Email: kgiersch@uke.de



## ***Berufserfahrung und Wissenschaftlicher Werdegang***

---

- |                              |   |
|------------------------------|---|
| Seit 02/2015<br>Hamburg      | <b>Post-Doc / Wissenschaftliche Mitarbeiterin am<br/>Universitätsklinikum Hamburg-Eppendorf</b> <ul style="list-style-type: none"><li>○ Arbeitsgruppe: Prof. Maura Dandri</li></ul>   |
| 08/2015<br>Paris, Frankreich | <b>Forschungsaufenthalt am Institut National<br/>de la Transfusion Sanguine (INTS)</b> <ul style="list-style-type: none"><li>○ Arbeitsgruppe: Prof. Camille Sureau</li></ul>  |
| 11/2011– 02/2015<br>Hamburg  | <b>Promotion zum Dr. rer. nat. am Universitätsklinikum<br/>Hamburg-Eppendorf</b> (Abschlussnote: magna cum laude) <ul style="list-style-type: none"><li>○ Arbeitsgruppe: Prof. Maura Dandri</li><li>○ Untersuchung von Hepatitis-D-Virusinfektionen im<br/>humanisierten Mausmodell</li></ul> |
| 07/2010 – 10/2011<br>Berlin  | <b>Wissenschaftliche Mitarbeiterin am Center for<br/>Cardiovascular Research, Charité Berlin</b> <ul style="list-style-type: none"><li>○ Arbeitsgruppe: Prof. Ulrich Kintscher</li></ul>  |
| 02/2010                      | <b>Approbation als Apothekerin</b>  |
| 10/2004 – 10/2008<br>Berlin  | <b>Pharmaziestudium an der Freien Universität Berlin</b>  |

## ***Praktika und Fortbildungen***

---

- |                                       |   |
|---------------------------------------|---|
| 02/2013<br>Edinburgh, UK              | <b>EASL Basic School of Hepatology:<br/>Stem Cells and the Liver</b>  |
| 05/2009 – 12/2009<br>Gainesville, USA | <b>Praktisches Jahr an der University of Florida<br/>(Department of Pharmaceutics)</b> <ul style="list-style-type: none"><li>○ Arbeitsgruppe: Prof. Sihong Song</li></ul> |

## ***Stipendien und Preise***

---

**Full Young Investigator Bursary** beim International Liver Congress der EASL in Amsterdam (2013), London (2014), Wien (2015), Barcelona (2016), Amsterdam (2017)

**Full Young Investigator Bursary** beim International Meeting on Molecular Biology of Hepatitis in Oxford (2012), Seoul (2016), Washington D.C. (2017)

**Top 10% Award** beim International Liver Congress der EASL, London, UK (2014)

## **Publikationen**

---

**Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo.** Allweiss L\*, [Giersch K\\*](#), Piroso A, Volz T, Muench RC, Beran RK, Urban S, Javanbakht H, Fletcher SP, Lütgehetmann M, Dandri M. Gut. 2021

**Murine hepatocytes do not support persistence of Hepatitis D virus mono-infection in vivo.** [Giersch K](#), Hermanussen L, Volz T, Kah J, Allweiss L, Casey J, Sureau C, Dandri M, Lütgehetmann M. Liver Int. 2021

**Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes.** Tham CYL, Kah J, Tan AT, Volz T, Chia A, [Giersch K](#), Ladiges Y, Loglio A, Borghi M, Sureau C, Lampertico P, Lütgehetmann M, Dandri M, Bertoletti A. Cell Rep Med. 2020

**High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort.** Bockmann JH, Grube M, Hamed V, von Felden J, Landahl J, Wehmeyer M, [Giersch K](#), Hall MT, Murray JM, Dandri M, Lüth S, Lohse AW, Lütgehetmann M, Schulze Zur Wiesch J. BMC Gastroenterol. 2020

**Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.** [Giersch K](#), Bhadra OD, Volz T, Allweiss L, Riecken K, Fehse B, Lohse AW, Petersen J, Sureau C, Urban S, Dandri M, Lütgehetmann M. Gut. 2019

**Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.** Winer BY, Shirvani-Dastgerdi E, Bram Y, Sellau J, Low BE, Johnson H, Huang T, Hrebikova G, Heller B, Sharon Y, [Giersch K](#), Gerges S, Seneca K, Pais MA, Frankel AS, Chiriboga L, Cullen J, Nahass RG, Lütgehetmann M, Toettcher JE, Wiles MV, Schwartz RE, Ploss A. Sci Transl Med. 2018

**Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.** Allweiss L, Volz T, [Giersch K](#), Kah J, Raffa G, Petersen J, Lohse AW, Beninati C, Pollicino T, Urban S, Lütgehetmann M, Dandri M. Gut. 2018

**Serum HBV pgRNA as a clinical marker for cccDNA activity.** [Giersch K](#), Allweiss L, Volz T, Dandri M, Lütgehetmann M. J Hepatol. 2017

**Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice.** [Giersch K](#), Homs M, Volz T, Helbig M, Allweiss L, Lohse AW, Petersen J, Buti M, Pollicino T, Sureau C, Dandri M, Lütgehetmann M. Sci Rep. 2017

**Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation.** Allweiss L, Gass S, [Giersch K](#), Groth A, Kah J, Volz T, Rapp G, Schöbel A, Lohse AW, Polywka S, Pischke S, Herker E, Dandri M, Lütgehetmann M. J Hepatol. 2016

**Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection** [Giersch K](#), Allweiss L, Volz T, Helbig M, Bierwolf J, Lohse AW, Pollok JM, Petersen J, Dandri M, Lütgehetmann M. J Hepatol. 2015

**Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte.** [Giersch K](#), Dandri M. J Clin Transl Hepatol. 2015

**Relevance of a full-length genomic RNA standard and a thermal-shock step for optimal hepatitis delta virus quantification.** Homs M\*, Giersch K\*, Blasi M, Lütgehetmann M, Buti M, Esteban R, Dandri M, Rodriguez-Frias F. J Clin Microbiol. 2014

**Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism.** Oehler N, Volz T, Bhadra OD, Kah J, Allweiss L, Giersch K, Bierwolf J, Riecken K, Pollok JM, Lohse AW, Fehse B, Petersen J, Urban S, Lütgehetmann M, Heeren J, Dandri M. Hepatology. 2014

**Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration.** Allweiss L, Volz T, Lütgehetmann M, Giersch K, Bornscheuer T, Lohse AW, Petersen J, Ma H, Klumpp K, Fletcher SP, Dandri M. J Hepatol. 2014

**Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection.** Giersch K\*, Helbig M\*, Volz T, Allweiss L, Mancke LV, Lohse AW, Polywka S, Pollok JM, Petersen J, Taylor J, Dandri M, Lütgehetmann M. J Hepatol. 2014

Hamburg, den 25.03.2021  
Dr. Katja Giersch